WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentPreface
View the documentIntroduction
Open this folder and view contentsParasitic infections
Open this folder and view contentsInsect and arachnid bites and stings
Open this folder and view contentsSuperficial fungal infections
Open this folder and view contentsSubcutaneous fungal infections
Open this folder and view contentsBacterial infections
Open this folder and view contentsViral infections
Close this folderEczematous diseases
View the documentContact dermatitis
View the documentAtopic dermatitis
View the documentSeborrhoeic dermatitis
Open this folder and view contentsScaling diseases
Open this folder and view contentsPapulosquamous diseases
View the documentCutaneous reactions to drugs
Open this folder and view contentsPigmentary disorders
Open this folder and view contentsPremalignant lesions and malignant tumours
Open this folder and view contentsPhotodermatoses
Open this folder and view contentsBullous dermatoses
View the documentAlopecia areata
View the documentUrticaria
Open this folder and view contentsConditions common in children
View the documentAcne vulgaris
View the documentPruritus
View the documentTropical ulcers
Open this folder and view contentsAntimicrobial drugs
Open this folder and view contentsAntifugal drugs
Open this folder and view contentsAntiseptic agents
Open this folder and view contentsKeratoplastic and keratolytic agents
Open this folder and view contentsScabicides and pediculicides
Open this folder and view contentsAnti-inflammatory and antipruritic drugs1
Open this folder and view contentsAntiallergics and drugs used in anaphylaxis
Open this folder and view contentsUltraviolet radiation-blocking agents (sunscreens)
Open this folder and view contentsMiscellaneous drugs
Open this folder and view contentsAnnex
View the documentSelected WHO Publications of Related Interest
View the documentBack cover
 

Atopic dermatitis

Atopic dermatitis, which often develops within the first few months of life, is a disease of unknown etiology. However, in many cases T-cell function is defective and serum IgE concentrations are elevated, which suggest that the immunological system is involved. Blockade of cutaneous β-adrenoreceptors has also been described. Other members of the immediate family are commonly affected, and relatives may have or may develop allergic rhinitis or asthma. The condition usually resolves spontaneously between the age of 5 and 8 years but it may persist into adulthood. Exacerbations may occur during periods of physical or emotional stress.

Weeping eczematous papules that are intensely pruritic develop in the face in infants, particularly on the cheeks. These lesions often extend to other skin surfaces later in childhood, including the scalp, wrists, flexor folds of the elbows and knees, and buttocks. Scratching leads to the formation of excoriations and infiltrated areas which subsequently become thickened or lichenified. Later, the lesions become drier, more scattered, and typically localized in the flexor folds of the neck, elbows, wrists and knees. Pustules and crusts are signs of secondary infection. Periorbital erythema and oedema are common.

Prevention and management

It is particularly important to explain to parents the chronic, relapsing nature of the disease and the factors that influence its course. Soaps, particularly those containing irritants or perfumes, should be avoided when washing children. Contact with detergents, domestic animals and clothes made from wool should also be avoided. Pruritus may be partially relieved by applying wet dressings to exudative lesions and emollients to lichenified plaques. If topical hydrocortisone, 1% concentration, is ineffective, the use of betamethasone valerate, other corticosteroids of comparable potency, or more potent corticosteroids such as oral prednisolone should be undertaken with care and with time-limitations to avoid side-effects. Topical antihistamines are not effective and should be avoided because of the risk of sensitization. However, oral antihistamines, particularly hydroxyzine, can be given at night to relieve pruritus and to facilitate sleep. Non-sedating antihistamines can be given during the day, and may provide some symptomatic relief. Since secondary staphylococcal infections, which can be subclinical or clinical, are common and can cause exacerbations, an oral antibiotic such as erythromycin can be given for 7-10 days (see Erythromycin - Dosage and administration), or a topical antibiotic such as mupirocin ointment can be applied to the skin.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 1, 2019